Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Teva fills CFO position as Desheh steps up to CEO

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Teva board agrees with CEO Jeremy Levin's decision to step down

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

New AstraZeneca CFO faces big task as generics squeeze and costs press

AstraZeneca has a new CFO to replace the departing Simon Lowth: Marc Dunoyer, who joined the company from GlaxoSmithKline earlier this year. He'll have plenty of work on his plate: The company's sales continue to slide on generic competition, it's in the middle of a cost-cutting plan and headquarters move, and more patent expirations are on their way.

Who wants to step into Teva's CEO hot seat?

In the aftermath of Teva CEO Jeremy Levin's departure announcement yesterday, media reports offer a few puzzle pieces that combine into one picture: Who in the world will the generics giant find to take on the job?

Teva CEO Jeremy Levin steps down amid board squabble

So much for denials. Monday, Teva Pharmaceutical Industries and CEO Jeremy Levin said he wasn't weighing a resignation. Today, the Israel-based company announced his imminent departure. Levin's exit comes in the wake of last week's layoffs announcement--and, so the story goes, amid a behind-the-scenes dust-up between Teva's board and management team.

Vertex to slash 370 jobs in shift away from hep C drug

What happened? A new wave of hepatitis C treatments, led by Gilead Sciences' sofosbuvir. Heartily backed by an FDA advisory panel Friday, sofosbuvir is first in a class of treatments aimed at shortening hep C treatment, boosting its effectiveness and easing its notorious side effects. The coming all-oral drug cocktails will shut out interferon--and shunt Incivek aside.

UPDATED: The ax drops at troubled Merck as big restructuring gets underway

The pink slips are starting to fly at Merck R&D. The rumor mill was running full tilt on Monday morning, with comments flowing across Twitter that planned layoffs are in the works. And a company spokesperson confirmed that the first of a planned wave of 8,500 in fresh job cuts are being made now.

Teva denies CEO weighing an exit over board's meddling

Clearly Israel is full of chatter about Teva Pharmaceutical Industries and its latest round of cost-cutting plans. The latest, according to an Israeli television report: CEO Jeremy Levin is considering making an exit. It's not the first such suggestion; During the company's second-quarter earnings call, Goldman Sachs analyst Jami Rubin wondered aloud about the board's support--or lack thereof--for Levin.

Eli Lilly's board elects multinational financial leader

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Teva ex-chairman: Execs should share layoffs pain with 10% pay cut

That Teva workers are striking to protest job cuts isn't all that unusual in the pharma business these days. That they're protesting executive pay is somewhat more unusual. That a prominent shareholder advises an accompanying pay cut for top executives and directors? That's definitely unusual.